by The global generative AI in personalized medicine market from 2023 to 2032, provides a comprehensive overview of the industry, market segmentation based on a variety of criteria, and the current vendor landscape.
Key Takeaways:
- North America is expected to dominate in the generative AI in personalized medicine market during the forecast period.
- By personalized medicine therapeutics, the pharmaceutical segment is expected to hold a leading position in the generative AI in personalized medicine market.
- By deployment model, the cloud-based segment is expected to carry a significant share of the generative AI in personalized medicine market during the forecast period.
- By end-user, the hospitals and clinics segment shares the maximum CAGR during the projection period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Generative AI in personalized medicine market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Generative AI in personalized medicine Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3095
Generative AI in Personalized Medicine Market Report Scope:
| Report Coverage | Details |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Personalized Medicine Therapeutics, By Deployment Model, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Gas Meter Market Size To Gain USD 22.4 Billion by 2032
The empirical study on the global Generative AI in personalized medicine market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Generative AI in personalized medicine Market. Our market report for the Generative AI in personalized medicine market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- Butterfly Network
- Deep Genomics
- Google LLC
- IBM Watson Health
- Microsoft Corporation
- Aidoc
- Insilico Medicine
- PathAI
- Tencent Holdings Ltd.
- Neuralink Corporation
- Johnson & Johnson
Data Sources and Methodology
To gather comprehensive insights on the Global Generative AI in personalized medicine Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Generative AI in personalized medicine Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Generative AI in personalized medicine market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Generative AI in Personalized Medicine Market Segmentation:
By Personalized Medicine Therapeutics
- Pharmaceutical
- Genomic Medicine
- Devices
By Deployment Model
- On-premise
- Cloud Based
By End-User
- Hospitals and Clinics
- Clinical Research
- Healthcare Organizations
- Diagnostic Centers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Generative AI in personalized medicine market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Generative AI in personalized medicine market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Generative AI in personalized medicine market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Generative AI in personalized medicine market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generative AI in Personalized Medicine Market
5.1. COVID-19 Landscape: Generative AI in Personalized Medicine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics
8.1. Generative AI in Personalized Medicine Market, by Personalized Medicine Therapeutics, 2023-2032
8.1.1 Pharmaceutical
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Genomic Medicine
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Devices
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Generative AI in Personalized Medicine Market, By Deployment Model
9.1. Generative AI in Personalized Medicine Market, by Deployment Model, 2023-2032
9.1.1. On-premise
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cloud Based
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Generative AI in Personalized Medicine Market, By End-User
10.1. Generative AI in Personalized Medicine Market, by End-User, 2023-2032
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Clinical Research
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Healthcare Organizations
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Diagnostic Centers
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Generative AI in Personalized Medicine Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 12. Company Profiles
12.1. Butterfly Network
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Deep Genomics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Google LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. IBM Watson Health
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Aidoc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Insilico Medicine
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. PathAI
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Tencent Holdings Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Neuralink Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
About Us:
Our team comprises a dedicated group of research analysts and management consultants who are driven by a unified vision: assisting individuals and organizations in realizing their strategic objectives, both immediate and long-term, through the provision of comprehensive research services. At Precedence Research, we have positioned ourselves to cater to the needs of a diverse range of entities, including established companies, startups, and non-profit organizations across various sectors. Our expertise extends to industries such as packaging, automotive, healthcare, chemicals and materials, industrial automation, consumer products, electronics and semiconductors, IT and telecommunications, and energy. With a wealth of experience within our ranks, our skilled analysts are equipped with extensive knowledge of the research landscape.
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
